← All trials
NCT05834777
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 11, 2023
- Primary completion
- Sep 1, 2025
- Completion date
- Dec 1, 2025
- First posted
- Apr 28, 2023
- Last posted
- Dec 18, 2023
- Enrollment
- 26
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Vanderbilt UniversityLead sponsor
- Renal Research InstituteCollaborator
- Renal Research InstituteOverall official - principal investigator
- Vanderbilt UniversityOverall official - principal investigator
- Vanderbilt UniversityReponsible party - principal investigator
- Pharvaris Netherlands B.V.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.